Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.72 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925696 | 0.90 | THRB (0.62) | KDRKMT2ATHRBALDH1A1LMNA | |
| SCHEMBL6921757 | 0.87 | KDR (0.73) | KDRMCHR1HRH3MEN1KMT2A | |
| SCHEMBL6924766 | 0.86 | MCHR1 (0.74) | KDRMCHR1HRH3NPC1ALDH1A1 | |
| SCHEMBL6925850 | 0.85 | MCHR1 (0.67) | KDRMCHR1MEN1KMT2ANPC1 | |
| SCHEMBL6808533 | 0.84 | MEN1 (0.71) | KDRMCHR1HRH3MEN1KMT2A | |
| SCHEMBL6924829 | 0.84 | MCHR1 (0.64) | KDRMCHR1ALDH1A1 | |
| SCHEMBL6922557 | 0.82 | KDR (0.50) | KDRMCHR1MEN1KMT2ANPC1 | |
| SCHEMBL13683778 | 0.80 | NPSR1 (0.63) | KDRMCHR1HRH3KMT2ANPC1 | |
| SCHEMBL6807188 | 0.79 | MCHR1 (0.71) | KDRMCHR1HRH3MEN1KMT2A | |
| SCHEMBL6925419 | 0.79 | MCHR1 (0.74) | KDRMCHR1HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | claimed |
| JP-2002511879-A | — | — | 2002-04-16 | — | — | JP | claimed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | disclosed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |